Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:18:27.880Z.
Calculation as of: 2026-10-06T22:18:27.880Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 651b3973db42e019715e3a8a4e975a06fcddd3d3dc4e12dda44c0d1ac22a80ea
PEG RATIO
N/A
Quantum BioPharma Ltd.
Market Cap
$19.77M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $19.77M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A |
| NextCure, Inc. (NXTC)vs › | $20.53M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
